Synvista Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.alteon.com
The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling
Phase 2
Completed
- Conditions
- HypertensionHypertrophy, Left Ventricular
- First Posted Date
- 2002-09-19
- Last Posted Date
- 2009-07-29
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 180
- Registration Number
- NCT00045994
The SAPPHIRE Study (Systolic And Pulse Pressure Hemodynamic Improvement By Restoring Elasticity)
Phase 2
Completed
- Conditions
- Hypertension
- First Posted Date
- 2002-09-19
- Last Posted Date
- 2010-03-26
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 450
- Registration Number
- NCT00045981
The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure
Phase 2
Completed
- Conditions
- Heart Failure, CongestiveDyspneaPulmonary Edema
- First Posted Date
- 2002-08-15
- Last Posted Date
- 2009-09-02
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 20
- Registration Number
- NCT00043836
- Locations
- 🇺🇸
Wake Forest University Baptist Medical Center, Department of Cardiology, Winston-Salem, North Carolina, United States
🇺🇸Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath